Skip to main content

Advertisement

SpringerLink
Log in

Neuroscience

Alzheimer's disease

  • News and Views Q&A
  • Published:

From Nature

View current issue Submit your manuscript

The neurodegenerative disorder Alzheimer's disease is becoming more prevalent in ageing populations worldwide. The identification of effective treatments will require a better understanding of the physiological mechanisms involved, and innovative approaches to drug development and evaluation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Some key players in the pathogenesis of AD.
Figure 2: The challenge of finding AD biomarkers.

FURTHER READING

  1. Alzheimer's Association 2009 Alzheimer's Disease Facts and Figures (2009).

  2. Chin, J., Roberson, E. D. & Mucke, L. in Learning and Memory: A Comprehensive Reference Vol. 4 (ed. Byrne, J. H.) Ch. 15 (Academic, 2008).

    Google Scholar 

  3. Mahley, R. W., Weisgraber, K. H. & Huang, Y. Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl Acad. Sci. USA 103, 5644–5651 (2006).

    Article  ADS  CAS  Google Scholar 

  4. Roberson, E. D. & Mucke, L. 100 years and counting: Prospects for defeating Alzheimer's disease. Science 314, 781–784 (2006).

    Article  ADS  Google Scholar 

  5. http://www.alzforum.org

  6. http://www.clinicaltrials.gov

Download references

Author information

Authors and Affiliations

  1. Lennart Mucke is at the Gladstone Institute of Neurological Disease and the Department of Neurology, University of California, San Francisco, California 94158, USA. lmucke@gladstone.ucsf.edu,

    Lennart Mucke

Authors
  1. Lennart Mucke
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author consults for Merck, has received research funding from Elan, and serves on the scientific advisory board of iPierian.

Additional information

See online at http://go.nature.com/phyLwm for more on neuroscience.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mucke, L. Alzheimer's disease. Nature 461, 895–897 (2009). https://doi.org/10.1038/461895a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/461895a

  • Springer Nature Limited

This article is cited by

Search

Navigation